Apitolisib PI3K Inhibitors
| Product name:GDC-0980 Apitolisib | Purity:98% min |
| CAS NO:1032754-93-0 | Solubility:DMSO : 14.29 mg/mL (28.66 mM) |
| Molecular Formula:C23H30N8O3S | Package:Package according to customer requirements |
| Molecular Weight:498.601 | Storage:Store at -20℃ |
Apitolisib, also known as GDC-0980 and RG7422; or GNE390, is a dual PI3 kinase/mTOR inhibitor, is also a n orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor GDC-0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR.
Related Products:
Everolimus; Temsirolimus; PI-103; Torin 1; PF-04691502; Torin 2; BGT226; Palomid 529; Deforolimus; KU-0063794; Rapamycin; Tacrolimus; LY294002
[1]. Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011, 54(21), 7579-7587.
[2]. Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther, 2011, 10(12), 2426-2436.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.